I.C.D. Laboratories Limited

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 08542807

		2026		2025
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		2,959		3,288
Investment Properties	5		30,000		30,000

			32,959		33,288
CURRENT ASSETS
Stocks	6	9,500		9,500
Debtors	7	4,550		52,824
Cash at bank and in hand		87,286		22,979

		101,336		85,303
Creditors: Amounts Falling Due Within One Year	8	(89,076 )		(87,819 )

NET CURRENT ASSETS (LIABILITIES)			12,260		(2,516 )

TOTAL ASSETS LESS CURRENT LIABILITIES			45,219		30,772

NET ASSETS			45,219		30,772

CAPITAL AND RESERVES
Called up share capital	9		100		100
Profit and Loss Account			45,119		30,672

SHAREHOLDERS' FUNDS			45,219		30,772

Page 1

Page 2

I.C.D. Laboratories Limited

Balance Sheet (continued)

As At 31 May 2026

For the year ending 31 May 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Kathryn Cavan

Director

27/07/2026

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

I.C.D. Laboratories Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08542807 . The registered office is 28 Terminus Road, Sheffield, South Yorkshire, S7 2LH.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings

2.4. Investment Properties

All investment properties are carried at fair value determined annually and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided for. Changes in fair value are recognised in the profit and loss account.

2.5. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

2.6. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

...CONTINUED

Page 3

Page 4

I.C.D. Laboratories Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 May 2026

2.6. Taxation - continued

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 2 (2025: )

4. Tangible Assets

	Fixtures & Fittings
	£
Cost
As at 1 June 2025	8,344

As at 31 May 2026	8,344

Depreciation
As at 1 June 2025	5,056
Provided during the period	329

As at 31 May 2026	5,385

Net Book Value
As at 31 May 2026	2,959

As at 1 June 2025	3,288

5. Investment Property

	2026
	£
Fair Value
As at 1 June 2025 and 31 May 2026	30,000

6. Stocks

	2026	2025
	£	£
Stock	9,500	9,500

7. Debtors

	2026	2025
	£	£
Due within one year
Other debtors	4,550	52,824

Page 4

Page 5

I.C.D. Laboratories Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 May 2026

8. Creditors: Amounts Falling Due Within One Year

	2026	2025
	£	£
Trade creditors	59,136	61,761
Other creditors	19,658	20,398
Taxation and social security	10,282	5,660

	89,076	87,819

9. Share Capital

	2026	2025
	£	£
Allotted, Called up and fully paid	100	100

10. Related Party Transactions

At the balance sheet date, an amount of £1324.00 (2025 £16824) was owed to

the company by Dore Trading Ltd, a company of which Ms K R Cavan, is also a Director. The loan was interest free and no repayment terms have been agreed at the balance sheet date.

At the balance sheet date, an amount of £6,000 (2025 -£15,000) was owed by

the company to Phyto Therapeutics Ltd, a company of which Ms K R Cavan, is also a Director. The loan was interest free and no repayment terms have been agreed at the balance sheet date.

At the balance sheet date, an amount of £1,000 (2025 -£20000.00) was owed by

the company to Kaytico Ltd, a company of which Ms K R Cavan, is also a Director. The loan was interest free and no repayment terms have been agreed at the balance sheet date.

Page 5